<DOC>
	<DOCNO>NCT00094055</DOCNO>
	<brief_summary>This Phase 2 study conduct multiple center United States . Patients thyroid cancer spread part body ( i.e. , metastatic ) eligible participate . Patients must disease control previous treatment radioactive iodine ( 131I ) good candidate treatment . The purpose study test whether angiogenesis inhibitor AG-013736 effective treatment metastatic thyroid cancer show number patient study experience significant durable tumor shrinkage .</brief_summary>
	<brief_title>Study Anti-angiogenesis Agent AG-013736 Patients With Metastatic Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Histologically document thyroid cancer metastasis . Failure radioactive iodine ( 131I ) control disease radioactive iodine ( 131I ) appropriate therapy ( e.g . due lack iodine uptake tumor ) Central lung lesion involve major blood vessel ( artery vein ) . ( Central lesion maintain structural integrity vessel potential bleed tumor lesion undergoes necrosis . MRI CT angiography use case question whether blood vessel involve . ) Patients history hemoptysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>